Medexus Pharmaceuticals (TSE:MDP) Upgraded by Leede Financial to Strong-Buy Rating

Leede Financial upgraded shares of Medexus Pharmaceuticals (TSE:MDP) from a moderate buy rating to a strong-buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2025 earnings at $0.29 EPS, FY2027 earnings at $0.69 EPS and FY2028 earnings at $1.30 EPS.

Several other equities analysts have also recently issued reports on the stock. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Stifel Nicolaus increased their price target on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Finally, Raymond James upgraded Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price on the stock in a research report on Wednesday, January 8th. One analyst has rated the stock with a buy rating and five have issued a strong buy rating to the company. Based on data from MarketBeat.com, Medexus Pharmaceuticals has a consensus rating of “Strong Buy” and an average price target of C$5.58.

Medexus Pharmaceuticals Stock Up 19.0 %

Shares of MDP stock opened at C$4.75 on Wednesday. The stock’s 50-day moving average price is C$3.14 and its 200 day moving average price is C$2.69. The stock has a market capitalization of C$116.52 million, a PE ratio of 95.00 and a beta of 1.96. Medexus Pharmaceuticals has a 52-week low of C$1.47 and a 52-week high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.